February 5, 2014 – Atlanta, GA – Addition of Executive with Extensive Experience in Virology Strengthens Capabilities in Growing Market for Hepatitis C and HIV Treatment. HealthStat Rx, one of the nation’s leading medication therapy management companies, announced today the hire of Amy Hampton as head of its Hepatitis C (HCV) business unit. This move further highlights HealthStat Rx’s commitment to leading treatment initiatives targeting HCV and HIV.

“Amy has a long history in the virology marketplace and is well versed on Hepatitis C therapies and protocols,” Marc O’Connor, HealthStat Rx COO, said. “She has a unique understanding of supporting patients living with chronic diseases. Her deep experience significantly strengthens our HCV services and helps ensure our leadership in improving outcomes through superior medication therapy management for Hepatitis C patients around the nation.”

HealthStat Rx is expanding its HCV program to account for ground-breaking new FDA approved therapies in the HCV therapeutic group. These new therapies, when managed properly, are capable of delivering cure level improvements to hundreds of thousands of lives.

“We also believe our HCV business unit has the capability to significantly increase HealthStat Rx’s growth,” O’Connor said.

Two new HCV therapies with significantly shortened treatment regimens received FDA approval in late 2013:  Sovaldi™, from Gilead Sciences and Olyssio™,from Janssen Therapeutics can treat chronic Hepatitis C infection in adults with up to a 90 percent cure rate in as little as 12 weeks.  Analysts are forecasting the global HCV market will grow from $4.7billion in 2012 to $17.7 billion in 2017. Growth will be propelled by increased diagnosis rates following more widespread screening and the introduction of more effective, tolerable agents.

“I have spent 12 years partnering with  community organizations, payors, public health clinics, specialty pharmacies, state and federal institutions, and group practices involved in HIV and Hepatitis C treatment,” stated Hampton.”At HealthStat Rx, we place patients at front and center of disease state management and empower them to improve their own outcomes through education, adherence and resource awareness.  The HealthStat Rx team focuses on making a difference in the lives of everyone we serve, including those living with Hepatitis C throughout the United States.  I am honored to be part of this team.” On LinkedIn

About HealthStat Rx

HealthStat Rx treats patients nationwide through its medication management protocols, including medication reconciliation and establishment of personalized medication regimens, and supports its provider partners and care coordination with its award-winning EMR, MedPlan™. HealthStats Rx healthcare professionals provide individualized care proven to improve the lives of chronically ill patients.